Cxbladder is a suite of easy-to-use and non-invasive genomic tests designed to help rule out urothelial bladder cancer, the most common form of the disease.
Cxbladder is an advanced laboratory test that analyzes five biomarker genes. The test can reduce the need for invasive procedures when patients are at a low risk of disease.
When should I use Cxbladder?
When tests reveal you have blood in your urine that is not visible to the naked eye (microhematuria).
When other tests for bladder cancer are inconclusive.
When you’re concerned about recurrent non-muscle invasive bladder cancer and undergoing regular surveillance cystoscopies.
When your cultural values or religious beliefs suggest a preference for discrete, non-invasive testing.
Why should I use Cxbladder?
To reduce the need for invasive procedures when you're at a low risk of disease.
To help ensure you get the care you need sooner, if further investigation is required.
To help resolve uncertainty, which may allow your doctor to confirm a diagnosis.
To reduce the burden of surveillance cystoscopy.
A sampling system designed to maximize comfort and convenience
Cxbladder's urine-based sampling system is quick and easy to use. The test is non-invasive and painless.
Learn more about Cxbladder
Contact our customer service team
Learn more about the benefits of genomic testing and Cxbladder availability in your region. If you’re concerned about bladder cancer, Cxbladder can provide reliable answers while helping to reduce the burden of invasive testing.
A precision test that delivers exceptional performance
Cxbladder is an advanced laboratory test that analyzes five biomarker genes to help rule out urothelial bladder cancer.
Leading clinicians around the world rely on Cxbladder. The Cxbladder suite of tests have now been used by over 5,000 urologists in more than 100,000 patients. Cxbladder is supported by over 20 years of research, and an evidence portfolio that includes more than 25 peer reviewed publications in leading medical journals.
Featured news
Survey: Surveillance Patients Show Strong Interest in Non-Invasive Test Options
In December 2023, using the Bladder Cancer Advocacy Network’s (BCAN’s) Patient Survey Network, we surveyed 1,507 US patients being monitored for non-muscle invasive bladder cancer (NMIBC). Those surveyed displayed a strong interest in non-invasive test options.
Learn more about Cxbladder
Contact our customer service team
Learn more about the benefits of genomic testing and Cxbladder availability in your region. If you’re concerned about bladder cancer, Cxbladder can provide reliable answers while helping to reduce the burden of invasive testing.